Gauss Partners with Truepill in Strategic Effort to Deliver At-Home COVID-19 Rapid Testing to Millions

By December 23, 2020 February 3rd, 2021 News

Partnership will enable eCommerce platform for ordering and fulfillment of rapid at-home tests to consumers’ doorsteps

Gauss, a leading developer of computer vision-aided diagnostics for healthcare, today announced its partnership with Truepill™, the digital health platform powering consumer health experiences through its API-connected infrastructure, to help facilitate the delivery of at-home COVID-19 rapid tests to customers’ doorsteps.

The partnership supports Gauss’s efforts to scale manufacturing and operations in advance of commercialization of its smartphone-powered at-home COVID-19 rapid antigen test, which has been submitted to the Food and Drug Administration (FDA) for Emergency Use Authorization (EUA).

“We want to be as ready as possible to deliver at-home rapid testing upon authorization,” said Siddarth Satish, Gauss Founder and CEO. “Public health officials and regulators are increasingly recognizing the potential impact of widely available at-home rapid antigen testing for COVID-19. We are working to produce a million tests over the next month and to scale to thirty million tests in the following quarter. Truepill will help provide the process and logistics infrastructure that enables us to deliver tests via a frictionless online consumer experience.”

Gauss previously announced its partnership with Cellex, Inc. on an at-home rapid antigen test that pairs a lateral flow assay for SARS-CoV-2 Antigen with a computer vision-enabled smartphone app in order to read the test result, allowing users to test themselves unassisted at home for active COVID-19 infection and obtain results in minutes.

The partnership with Truepill will launch with an eCommerce platform enabling users to buy tests online from their homes and will leverage Truepill’s systems and logistics infrastructure to enable processing of customer orders, integration with telehealth services, and same-day shipment of orders for home delivery. The integration will also enable Gauss to seamlessly process and fulfill digital orders from enterprise customers, such as third-party telehealth platforms.

Once they receive a test, users follow step-by-step video instructions in a smartphone app to correctly collect a nasal swab sample and perform a rapid antigen test. After 15 minutes, the app prompts users to scan their rapid test with their smartphone and the scanned image is analyzed with Gauss’s computer vision and neural network algorithms to generate a final test result. The app informs the user if the test result is negative or positive for SARS-CoV-2 antigens within seconds. A clinical trial submitted by Gauss to FDA for Emergency Use Authorization reported a 94.4% sensitivity and 99.2% specificity compared to a high-sensitivity RT-PCR.

“At Truepill, we’re inspired by partners who solve big problems with innovative solutions,” said Sid Viswanathan, Co-Founder and President of Truepill. “Scale and speed are essential to combat this pandemic, and we’re thrilled to partner with Gauss to provide the infrastructure needed to deliver their rapid, at-home antigen tests to millions of consumers across the country. This new program exemplifies the power of technology in healthcare, epitomizing what’s possible when we work together to empower patients with accessible, affordable solutions.”

Learn more about the Gauss/Cellex at-home rapid antigen test at

Note that an Emergency Use Authorization is not an FDA approval or clearance of a product but allows commercialization of the product for the duration of the declared public health emergency.